Core Viewpoint - Aidi Pharmaceutical has received approval for the listing application of the raw material drug Dolutegravir Sodium, which is part of its high-end generic drug development project for HIV [1] Group 1: Company Developments - Aidi Pharmaceutical's wholly-owned subsidiary, Yangzhou Aidi Pharmaceutical Technology Co., Ltd., has been granted the "Chemical Raw Material Drug Listing Application Approval Notice" by the National Medical Products Administration [1] - The approved raw material Dolutegravir Sodium is intended for use in domestic formulations, ensuring the supply and quality of the raw material while reducing production costs [1] - If the generic version of Dolutegravir Sodium tablets is approved for market launch, it will enhance the variety of anti-HIV drugs and clinical options offered by the company [1]